Bristol Myers settles HIV antitrust suit, but J&J, Gilead still await their day in court

The first of the three pharma juggernauts accused by prominent AIDS and gay rights activist Peter Staley of monopolizing the market for human immunodeficiency virus (HIV) drugs is putting its legal woes to bed.

Bristol Myers Squibb will hand over up to $11 million to settle a lawsuit claiming it, Gilead Sciences and Johnson & Johnson used anticompetitive marketing tactics to block generic competition to HIV drugs. Importantly, the other two companies aren't involved in the settlement.